These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22934796)

  • 1. Interferon-free hepatitis C therapy: how close are we?
    Pockros PJ
    Drugs; 2012 Oct; 72(14):1825-31. PubMed ID: 22934796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt.
    Kanda T; Matsuoka S; Moriyama M
    Hepatol Int; 2018 Jul; 12(4):291-293. PubMed ID: 29992512
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.
    Florian J; Mishra P; Arya V; Harrington P; Connelly S; Reynolds KS; Sinha V
    Clin Pharmacol Ther; 2015 Oct; 98(4):394-402. PubMed ID: 26179495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.
    Shahid I; Ibrahim MM
    Curr Mol Med; 2018; 18(7):409-435. PubMed ID: 30608042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.
    Flisiak R; Flisiak-Jackiewicz M
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):559-567. PubMed ID: 28317409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of interferon in the new era of hepatitis C treatments.
    Parekh PJ; Shiffman ML
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):649-56. PubMed ID: 24758387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and management of treatment failure to new oral hepatitis C drugs.
    Benítez-Gutiérrez L; Barreiro P; Labarga P; de Mendoza C; Fernandez-Montero JV; Arias A; Peña JM; Soriano V
    Expert Opin Pharmacother; 2016 Jun; 17(9):1215-23. PubMed ID: 27149603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
    Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
    Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals.
    Jhaveri MA; Manne V; Kowdley KV
    Drugs Aging; 2018 Feb; 35(2):117-122. PubMed ID: 29417462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of
    Antwi SO; Van Houten HK; Sangaralingham LR; Patel T
    Cancer Prev Res (Phila); 2019 Dec; 12(12):891-902. PubMed ID: 31451519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
    Jensen DM; Brunda M; Elston R; Gane EJ; George J; Glavini K; Hammond JM; Le Pogam S; Nájera I; Passe S; Piekarska A; Rodriguez I; Zeuzem S; Chu T;
    Liver Int; 2016 Apr; 36(4):505-14. PubMed ID: 26519669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting.
    Cooper C
    Clin Infect Dis; 2012 Aug; 55(3):418-25. PubMed ID: 22491342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status of treatment of chronic hepatitis C and related challenges in the "Pre-DAA Era" in China].
    Hu P; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):869-873. PubMed ID: 27978936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.
    Zeng H; Li L; Hou Z; Zhang Y; Tang Z; Liu S
    Int J Med Sci; 2020; 17(7):892-902. PubMed ID: 32308542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New triple therapy in chronic hepatitis C. Increased patient chances].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Sep; 153(39):20. PubMed ID: 21991830
    [No Abstract]   [Full Text] [Related]  

  • 20. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.